English | عربي
  Add to Twitter
Takeda’s Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial    
− Takeda’s dengue vaccine candidate (TAK-003) was efficacious in preventing dengue fever in children and adolescents living in dengue-endemic countries in the ongoing Phase 3 trial –

− The vaccine candidate was found to be well tolerated with no significant safety concerns identified in analyses to date –

− Details will be published in a peer-reviewed journal –